BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

BML Capital Management LLC reduced its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 42.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 228,500 shares of the biopharmaceutical company's stock after selling 169,780 shares during the period. Vanda Pharmaceuticals comprises approximately 0.6% of BML Capital Management LLC's holdings, making the stock its 19th biggest holding. BML Capital Management LLC owned 0.39% of Vanda Pharmaceuticals worth $1,072,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sei Investments Co. increased its stake in Vanda Pharmaceuticals by 39.6% in the 1st quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company's stock valued at $2,132,000 after buying an additional 147,066 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in shares of Vanda Pharmaceuticals during the 1st quarter worth about $1,158,000. Acadian Asset Management LLC lifted its position in shares of Vanda Pharmaceuticals by 4.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company's stock worth $9,740,000 after buying an additional 107,203 shares in the last quarter. Monaco Asset Management SAM purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $1,090,000. Finally, Empowered Funds LLC boosted its position in Vanda Pharmaceuticals by 8.2% during the first quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company's stock valued at $827,000 after buying an additional 15,215 shares during the period. Institutional investors and hedge funds own 88.14% of the company's stock.

Vanda Pharmaceuticals Trading Up 1.1 %

Shares of VNDA traded up $0.06 during trading hours on Tuesday, hitting $5.40. 990,147 shares of the stock traded hands, compared to its average volume of 1,306,135. The firm has a market capitalization of $314.77 million, a PE ratio of -19.46 and a beta of 0.77. Vanda Pharmaceuticals Inc. has a 1-year low of $3.32 and a 1-year high of $6.75. The business has a fifty day moving average of $4.79 and a 200-day moving average of $5.25.

Analysts Set New Price Targets

VNDA has been the topic of several recent analyst reports. HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, October 31st. They set a "buy" rating and a $18.00 price objective on the stock. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research report on Saturday. They set a "hold" rating for the company. Finally, Cantor Fitzgerald upped their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an "overweight" rating in a report on Thursday, August 1st.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.